WEREWOLF THERAPEUTICS INC (HOWL)
US95075A1079 - Common Stock
HOWL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. HOWL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HOWL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
HOWL had negative earnings in the past year.
In the past year HOWL has reported a negative cash flow from operations.
In the past 5 years HOWL always reported negative net income.
In the past 5 years HOWL always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -44.36%, HOWL perfoms like the industry average, outperforming 51.53% of the companies in the same industry.
Looking at the Return On Equity, with a value of -69.50%, HOWL is in line with its industry, outperforming 56.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.36% | ||
| ROE | -69.5% | ||
| ROIC | N/A |
ROA(3y)-55.86%
ROA(5y)-56.17%
ROE(3y)-69.9%
ROE(5y)-85.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for HOWL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HOWL does not have a ROIC to compare to the WACC, probably because it is not profitable.
HOWL has more shares outstanding than it did 1 year ago.
The debt/assets ratio for HOWL is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -3.62, we must say that HOWL is in the distress zone and has some risk of bankruptcy.
HOWL has a Altman-Z score (-3.62) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.29 indicates that HOWL is not too dependend on debt financing.
HOWL has a worse Debt to Equity ratio (0.29) than 69.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.62 |
ROIC/WACCN/A
WACC11.57%
2.3 Liquidity
A Current Ratio of 10.10 indicates that HOWL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.10, HOWL belongs to the best of the industry, outperforming 81.26% of the companies in the same industry.
HOWL has a Quick Ratio of 10.10. This indicates that HOWL is financially healthy and has no problem in meeting its short term obligations.
HOWL has a Quick ratio of 10.10. This is amongst the best in the industry. HOWL outperforms 81.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.1 | ||
| Quick Ratio | 10.1 |
3. Growth
3.1 Past
The earnings per share for HOWL have decreased strongly by -36.36% in the last year.
The Revenue for HOWL has decreased by -86.84% in the past year. This is quite bad
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.22%
Revenue 1Y (TTM)-86.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to decrease by -9.43% on average over the next years.
The Revenue is expected to grow by 13.49% on average over the next years. This is quite good.
EPS Next Y-53.33%
EPS Next 2Y-34.58%
EPS Next 3Y-17.59%
EPS Next 5Y-9.43%
Revenue Next Year-90.78%
Revenue Next 2Y-64.83%
Revenue Next 3Y-21.13%
Revenue Next 5Y13.49%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
HOWL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HOWL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HOWL's earnings are expected to decrease with -17.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.58%
EPS Next 3Y-17.59%
5. Dividend
5.1 Amount
No dividends for HOWL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
WEREWOLF THERAPEUTICS INC
NASDAQ:HOWL (1/6/2025, 5:34:24 PM)
After market: 1.6898 +0.07 (+4.31%)1.62
-0.06 (-3.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners73.55%
Inst Owner Change0%
Ins Owners1.55%
Ins Owner Change0%
Market Cap72.19M
Analysts88.33
Price Target12.24 (655.56%)
Short Float %3.64%
Short Ratio1.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.66%
Min EPS beat(2)-4.3%
Max EPS beat(2)9.61%
EPS beat(4)2
Avg EPS beat(4)5.29%
Min EPS beat(4)-9.56%
Max EPS beat(4)25.39%
EPS beat(8)6
Avg EPS beat(8)24.35%
EPS beat(12)8
Avg EPS beat(12)16.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-33.46%
Min Revenue beat(2)-100%
Max Revenue beat(2)33.09%
Revenue beat(4)1
Avg Revenue beat(4)-37.83%
Min Revenue beat(4)-100%
Max Revenue beat(4)33.09%
Revenue beat(8)4
Avg Revenue beat(8)70.68%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.56%
EPS NY rev (1m)0%
EPS NY rev (3m)5.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-73.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-45.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 21.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.81 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0.08
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.36% | ||
| ROE | -69.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-55.86%
ROA(5y)-56.17%
ROE(3y)-69.9%
ROE(5y)-85.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 17.97% | ||
| Cap/Sales | 9.75% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.1 | ||
| Quick Ratio | 10.1 | ||
| Altman-Z | -3.62 |
F-Score3
WACC11.57%
ROIC/WACCN/A
Cap/Depr(3y)199.68%
Cap/Depr(5y)374.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.22%
EPS Next Y-53.33%
EPS Next 2Y-34.58%
EPS Next 3Y-17.59%
EPS Next 5Y-9.43%
Revenue 1Y (TTM)-86.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-90.78%
Revenue Next 2Y-64.83%
Revenue Next 3Y-21.13%
Revenue Next 5Y13.49%
EBIT growth 1Y-62.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.34%
EBIT Next 3Y-28.99%
EBIT Next 5Y-16.85%
FCF growth 1Y-4.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5YN/A